News

12/12/2017

Why EMA can do more for clinical trial subjects

Malpractices in clinical trials are still common. In October, three Members of the European Parliament requested the European Medicines Agency to address these issues. The agency’s reply to the letter still leaves Wemos concerned. Read more

News

6/12/2017

More influence on health care for businesses

Businesses and private investors are increasingly involved in public health issues worldwide. Civil society organizations and experts share their concerns about this in Barcelona this week. Wemos is one of these organizations. Read more

Blog

28/11/2017

Health systems advocacy from inside the story

‘A good health system finds people where they are, it is easily accessible when and how people need it,’ stated Amanda Banda during the first Global Health Café Read more

Blog

22/11/2017

Medicijnen in de Tweede Kamer

Vandaag vindt in de Tweede Kamer een Algemeen Overleg geneesmiddelenbeleid plaats. Vooruitlopend op het overleg organiseerde Wemos vorige week in de Tweede Kamer een bijeenkomst over het belang van voorwaarden verbinden aan publieke investeringen in medicijnen. Read more

Blog

16/11/2017

Why lack of money is draining African health sectors

If you had to wait twelve hours to pay a visit to your physician, would you return the next time? Or if a midwife yelled at you during labour, or your prescription drugs were never available at your local pharmacy? In the African health sector, these scenarios are not uncommon. We talked about health care in Africa with the Nigerian PhD student Oluwasegun Jko Ogundele, who paid a visit to Wemos earlier this month. Read more

News

26/10/2017

Global health cafes: join the debate on health workers

A new series of global health debates – Global Health Cafes – will kick off on Monday November 20th at the Royal Tropical Institute (KIT). The series is a joint collaboration between Vice Versa, Wemos and other civil society organizations. Read more

News

12/10/2017

European medicines agency must protect vulnerable clinical trial participants

In a letter to the director of the European Medicines Agency (EMA), three Members of European Parliament (MEPs) have expressed their concerns about vulnerable clinical trial participants in low- and middle-income countries. Read more

News

5/10/2017

European Parliament rejects criteria endocrine-disrupting chemicals

The European Parliament has rejected the European Commission’s proposed criteria for identifying endocrine-disrupting chemicals. These criteria, in their current form, would not sufficiently protect our health. Read more

News

28/9/2017

EU criteria for endocrine-disrupting chemicals will not protect health

The European Commission’s proposed criteria for identifying endocrine-disrupting chemicals should be amended, as they will not protect the health of European citizens. Read more